CN106318997A - Efficient preparation and purification method of thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP - Google Patents
Efficient preparation and purification method of thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP Download PDFInfo
- Publication number
- CN106318997A CN106318997A CN201510383060.0A CN201510383060A CN106318997A CN 106318997 A CN106318997 A CN 106318997A CN 201510383060 A CN201510383060 A CN 201510383060A CN 106318997 A CN106318997 A CN 106318997A
- Authority
- CN
- China
- Prior art keywords
- cgamp
- phosphoric acid
- seleno
- nucleotide
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims description 7
- 238000000746 purification Methods 0.000 title claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title abstract description 22
- 229910000147 aluminium phosphate Inorganic materials 0.000 title abstract description 9
- 239000002773 nucleotide Substances 0.000 title abstract description 9
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 6
- JRPHGDYSKGJTKZ-UHFFFAOYSA-N selenophosphoric acid Chemical compound OP(O)([SeH])=O JRPHGDYSKGJTKZ-UHFFFAOYSA-N 0.000 claims abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 3
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 3
- 229960005305 adenosine Drugs 0.000 abstract description 3
- 239000012190 activator Substances 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 102000003960 Ligases Human genes 0.000 abstract 1
- 108090000364 Ligases Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 238000009509 drug development Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 239000001226 triphosphate Substances 0.000 abstract 1
- 235000011178 triphosphate Nutrition 0.000 abstract 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 abstract 1
- ZQRRBZZVXPVWRB-UHFFFAOYSA-N [S].[Se] Chemical compound [S].[Se] ZQRRBZZVXPVWRB-UHFFFAOYSA-N 0.000 description 12
- 108090000467 Interferon-beta Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000003996 Interferon-beta Human genes 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 229960001388 interferon-beta Drugs 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 4
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 101100478890 Caenorhabditis elegans smo-1 gene Proteins 0.000 description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 3
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 3
- 101150102102 SMT3 gene Proteins 0.000 description 3
- 101150096255 SUMO1 gene Proteins 0.000 description 3
- 101100408688 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmt3 gene Proteins 0.000 description 3
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000053227 Themus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229940029575 guanosine Drugs 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- -1 5 g/L) Chemical compound 0.000 description 1
- 101150031621 CGAS gene Proteins 0.000 description 1
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101000937305 Drosophila melanogaster Protein aubergine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010032038 Interferon Regulatory Factor-3 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- JLQNHALFVCURHW-UHFFFAOYSA-N cyclooctasulfur Chemical compound S1SSSSSSS1 JLQNHALFVCURHW-UHFFFAOYSA-N 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- CNFDGXZLMLFIJV-UHFFFAOYSA-L manganese(II) chloride tetrahydrate Chemical compound O.O.O.O.[Cl-].[Cl-].[Mn+2] CNFDGXZLMLFIJV-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
Abstract
The invention belongs to the field of bioengineering technology, and in particular discloses a method for efficiently preparing and purifying thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP by virtue of bio-enzyme catalysis. According to the method disclosed by the invention, firstly, a biological enzyme, namely cyclic di-nucleotide cGAMP synthetase (cGAS), is subjected to mass production by virtue of genetic engineering technology so as to subsequently synthesize adenosine (vernine) 5'-([alpha]-thio-/seleno-phosphoric acid) triphosphate, and then efficient and specific thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP is synthesized by conducting catalysis with the biological enzyme cGAS; therefore, the method for preparing the thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP is provided, and the method is large in scale, high in yield, low in cost, mild in conditions and is rapid and convenient. The thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP prepared by the invention, as an effective activator for STING in a human natural immune signaling pathway cGAS-STING-IRF3, is capable of activating and enhancing the natural autoimmune system; the thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP has relatively broad bio-activities of resisting viruses, resisting tumors and the like; and the thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP has a good drug development prospect.
Description
Technical field
The invention belongs to technical field of bioengineering, be specially that one uses catalyzed by biological enzyme efficiently to prepare, purification sulfur (selenium) is for the method for phosphoric acid ring dinucleotide cGAMP.
Background technology
The nucleic acid of antibacterial and virus can cause host immune response, and host starts immunoreation by the nucleic acid sensing producing pathogen.Recent studies have shown that cyclo GMP-AMP synzyme (cGAS) is the cytoplasmic DNA sensor of a kind of key.CGAS is activated by double-stranded DNA, catalyzes and synthesizes a kind of non-classical ring dinucleotide 2 ', 3 '-cGAMP.CGAMP is combined promotion to interferon beta and the sensing of other cytokines as second message,second messenger by the receptor protein STING on endoplasmic reticulum.Model about STING regulation signal conduction shows that the combination of receptor can cause the conformation change of STING, causes convening and activating of protein kinase TBK1 in Signaling complex.Transcription factor IRF3 entering signal complex the most therewith by TBK1 phosphorylation, the IRF3 of phosphorylation forms oligomer and is transported in nucleus, starts the expression of interferon beta.Interferon beta can regulate and control the expression more than 200 kinds of interferon-stimulated genes, they can down-regulation protein matter synthesis, promote cell growth arrest and inducing cell apoptosis, thus the state forming a kind of antiviral controls the propagation of virus.
Research in the model of STING mediation signal conduction shows, the combination of cGAMP can cause STING that allosteric effect occurs, thus cause enrichment and the activation of protein kinase TBK1 in Signaling complex, and then cause transcription factor interferon regulatory factor 3(IRF3) phosphorylation, the IRF3 of phosphorylation can occur oligomerization and be transported in nucleus, it can induce the expression of interferon-β (IFN-β) in nucleus, and the expression of IFN-β cytokine gene interferon-induced to kind more than 200 has regulation effect, thus by the expression of albumen in downward tumor cell, growth of tumour cell is stagnated and inducing apoptosis of tumour cell is to embody its antineoplastic function.IFN-β has been applied to the clinical treatment of leukemia, multiple sclerosis etc. by FDA approval, and cGAMP is as the activator of STING, strengthens human body innate immunity, the up-regulated expression of induction I-type interferon, and then activates T cell.Therefore, cGAMP has the huge potential quality being applied to antitumor clinical treatment.Two nearest researchs show that the cytoplasmic DNA sensing depending on STING path can regulate the innate immunity identification function for immunogenic cancer cell, and the immunological effect that can rely on by activating I type interferon becomes the complementary therapy of radiation treatment.Dendritic cell is the internal topmost class antigen-presenting cell presenting tumor associated antigen, and when dendritic cell is exposed to danger or inflammatory signals, they have high susceptibility to this task, it is possible to cause the cross activation of CD8+ T cell to react.I type interferon (comprising interferon-ALPHA and interferon beta) is as a class well-known immune activation factor family, it is possible to the cross immunity of Dendritic Cells Induced is produced maximally effective activation.Recent internal and in vitro study all shows that the interferon-induced dendritic cell cross-immune reaction for tumor specific antigen of I type is the mechanism of a kind of key of tumour immunity monitoring, and can promote the tumor-killing effect of CD8+ T cell.Recently, we have discovered that sulfur (selenium) shows the antitumor more higher than cGAMP, antiviral activity for phosphoric acid ring dinucleotide cGAMP.Therefore, sulfur (selenium) has potential significant application value for phosphoric acid ring dinucleotide cGAMP at antitumor, antiviral drugs development field.
Summary of the invention
1. prepared by the scale of Mus source cGAMP synzyme cGAS
2, using the Mus source ring dinucleotide cGMP-AMP synzyme cGAS catalysis of restructuring, scale prepares sulfur (selenium) for phosphoric acid ring dinucleotide cGAMP.
3, sulfur (selenium) is for phosphoric acid ring dinucleotide cGAMP high efficiency separation and purification method.
Accompanying drawing explanation
Figure
1
It is that sulfur (selenium) is for phosphoric acid ring dinucleotide
cGAMP
Molecular structure
Detailed description of the invention
Embodiment
1
: Mus source
cGAMP
Synzyme
cGAS
Efficient preparation
( 1 )Mus source ring dinucleotide cGAMP synzyme cGAS gene is bought from ATCC company of the U.S., by genetic engineering means by its successful clone to pET-28 (a) carrier being purchased from Novagen company, Mus cGAS gene N-end is with SMT3 fusion tag, containing 6 histidine Ni-NTA post affinity tag on SMT3 label protein.Gene sequencing result shows that we successfully construct Mus source ring dinucleotide cGAMP synzyme cGAS gene expression plasmid.
( 2 )Inoculation: (be purchased from Novagen company) with e. coli bl21 (DE3) as Host Strains, convert, choose speckle in LB culture medium culturing.The LB culture fluid that shake flask culture concentration is 25 g/L for inoculation.Shaking flask is placed in full temperature control shaking table, and 240 rpm shaken cultivation are overnight.The OD600 measured value of seed is between 2-4.Inoculum concentration is the 2%-5% of working volume.
( 3 )Fermentor cultivation E. coli expressing protein:
Desk-top fermentation cylinder is used to cultivate 20 L tank bodies and the Rushton stirring paddle of E. coli feeding culture.Control and regulation speed of agitator, temperature, pH, dissolved oxygen, foam/liquid level, three peristaltic pumps and ventilations etc..It is provided that supply control by a thermal mass gas flow meters (TMFC).Initial incubation based component is: sodium dihydrogen phosphate (NaH2PO4,3.5 g/L), disodium hydrogen phosphate (Na2HPO4,5.0 g/L), ammonium sulfate ((NH4) 2SO4,5.0 g/L), yeast extract (5.0 g/L), defoamer.After high temperature sterilize cooling, add: magnesium sulfate (25% solution, ultimate density is 4 ml/L), glucose, (10g/L, it is usually added into the solution of 50%), K-12 trace meter (ultimate density is 1 ml/L), thiamine (addition determines according to Stock concentrations, and ultimate density is 2.2 mg/L), calcium chloride dihydrate (addition determines according to Stock concentrations, and ultimate density is 0.15g/L).[K-12 Trace Metal solution, including: sodium chloride (NaCl, 5 g/L), zinc sulphate heptahydrate (ZnSO4-7H2O, 1 g/L), manganese chloride tetrahydrate (MnCl2-4H2O, 4 g/L), Iron trichloride hexahydrate (FeCl3-6H2O, 4.75 g/L), copper sulphate pentahydrate (CuSO2-5H2O, 0.4 g/L), boric acid (H3BO3,0.575 g/L), Sodium Molybdate Dihydrate (NaMoO4-2H2O, 0.5 g/L), 6N sulphuric acid (H2SO4, ~ 12.5 ml/L).】
Control pre-set parameter: fermentation the operation time be 22 hours, control temperature be 37 ° of C, pH be 7.0, DO is 30%.Initial speed of agitator is 200rpm, is controlled rotating speed by DO association thereafter.After initial incubation 5 hours, proceeding by feeding culture, after fermenting 5 hours, along with exhausting of carbon source, pH value terminates in 7.1, and BioCommand Automatic Program opens feed supplement pump.DO and pH is also accurately controlled.The dry cell weight cultivating E. coli acquisition is 25 g/L.
( 4 ) Mus sourceCGAS pheron purification
Somatic cells is dissolved in 50mM Tris.HCl(pH 7.5), use cell crushing instrument smudge cells, protein-contg supernatant is obtained after high speed centrifugation, then it being purchased from Qiagen company with Ni-NTA() affinity column initial gross separation purifies cGAS albumen, with SDS-Page analyzing proteins purity (85%), and then remove SMT3 fusion tag albumen with SUMO protease (being purchased from Qiagen company) enzyme action, then it is isolated and purified to carry out second time Ni-NTA affinity column.Finally use HiLoadTMSuperdex 75 gel column is further purified, and obtains 95% purity cGAS pheron, preserves and-80 degree ultralow temperature refrigerators after lyophilization.
Embodiment
2:
Adenosine
(
Guanosine
)5
’
-
The preparation of α sulfur generation (seleno) tricresyl phosphate phosphoric acid
Adenosine (guanosine) 5 '-α sulfur generation (seleno) tricresyl phosphate phosphoric acid according to literature method synthesis (Caton-Williams Julianne etc., Science China, Chemistry,
2012, 55(1), 80-89; Boyle Nicholas A., Nucleosides, Nucleotides and Nucleic
Acids, 2005, 24, 1651-1664.)。
Embodiment
3:
Use the Mus source ring dinucleotide of restructuring
cGMP-AMP
Synzyme
cGAS
Catalysis
,
Prepare sulfur
(
Selenium
)
For phosphoric acid ring dinucleotide
cGAMP
Use the Mus source restructuring cGAS enzyme catalysis of preparation, prepare sulfur (selenium) the most in specific manner for phosphoric acid ring dinucleotide cGAMP.Reaction system is 20 liters of biological enzyme reactors, reaction system (10 mM) Han Mus source cGAS, adenosine 5 '-α sulfur generation (seleno) tricresyl phosphate disodic alkaliine (10 mM), GTP [or guanosine 5 '-α sulfur generation (seleno) tricresyl phosphate disodic alkaliine] (10 mM), MgCl2 (10 mM)
DNA (0.2mg/ml), NaCl (100 mM), reaction temperature 37 degree, 8 hours time.With spectrophotometer in 260nm detection product and reactant, reaction yield more than 95%.
4
, sulfur
(
Selenium
)
For phosphoric acid ring dinucleotide
cGAMP
Scale high efficiency separation and purification method
Isolated and purified with 100 milliliters of bulk ionic exchange columns (being purchased from GE company), gradient elution sulfur (selenium), for phosphoric acid ring dinucleotide cGAMP, obtains the purity sulfur (selenium) higher than 95% for phosphoric acid ring dinucleotide cGAMP.About 250 grams of sulfur (selenium) are obtained for phosphoric acid ring dinucleotide cGAMP lyophilizing white powder samples after-50 degree freezer dryer lyophilizations.
Claims (4)
1. the efficient large-scale preparation method of sulfur generation (seleno) phosphoric acid ring dinucleotide cGAMP.
2. the high efficiency preparation method of Mus source cGAMP synzyme cGAS.
3. using ring dinucleotide cGAMP synzyme cGAS catalysis, the method for sulfur generation (seleno) phosphoric acid ring dinucleotide cGAMP is prepared in scale.
4. sulfur generation (seleno) phosphoric acid ring dinucleotide cGAMP high efficiency separation and purification method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510383060.0A CN106318997A (en) | 2015-07-03 | 2015-07-03 | Efficient preparation and purification method of thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510383060.0A CN106318997A (en) | 2015-07-03 | 2015-07-03 | Efficient preparation and purification method of thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106318997A true CN106318997A (en) | 2017-01-11 |
Family
ID=57726986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510383060.0A Withdrawn CN106318997A (en) | 2015-07-03 | 2015-07-03 | Efficient preparation and purification method of thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106318997A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299512B2 (en) | 2016-03-18 | 2022-04-12 | Immunesensor Therapeutics, Inc. | Cyclic di-nucleotide compounds and methods of use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014099824A1 (en) * | 2012-12-19 | 2014-06-26 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| CN106309484A (en) * | 2015-07-02 | 2017-01-11 | 聊城市奥润生物医药科技有限公司 | Application of sulfo-(seleno) phosphate cyclic dinucleotide cGAMP in cancer-treating drug combination |
-
2015
- 2015-07-03 CN CN201510383060.0A patent/CN106318997A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014099824A1 (en) * | 2012-12-19 | 2014-06-26 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| CN106309484A (en) * | 2015-07-02 | 2017-01-11 | 聊城市奥润生物医药科技有限公司 | Application of sulfo-(seleno) phosphate cyclic dinucleotide cGAMP in cancer-treating drug combination |
Non-Patent Citations (2)
| Title |
|---|
| XIN CAI 等: "The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling", 《MOLECULAR CELL》 * |
| XIN LI 等: "Cylic GMP-AMP Synthase is Activated by Double-stranded DNA-Induced Oligomerization", 《IMMUNITY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299512B2 (en) | 2016-03-18 | 2022-04-12 | Immunesensor Therapeutics, Inc. | Cyclic di-nucleotide compounds and methods of use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104419701B (en) | The quick assemble method of the yeast of multiple clips DNA | |
| CN107916283A (en) | A kind of production technology of niacinamide | |
| WO2020135747A1 (en) | Optimized in vitro cell-free protein synthesis system and application thereof | |
| CN108535489A (en) | A kind of albumen synthetic system for protein synthesis in vitro, kit and preparation method thereof | |
| CN110551781A (en) | Method for preparing 5' -guanylic acid by enzyme method | |
| CN116555147A (en) | Construction method and application of recombinant escherichia coli for high yield of N-acetylneuraminic acid | |
| CN106434585A (en) | Glucosamine-6-phosphate synthetase mutant | |
| CN106190999A (en) | The high efficiency preparation method of ring dinucleotide cGAMP | |
| CN106318997A (en) | Efficient preparation and purification method of thio- (seleno-) phosphoric acid cyclic di-nucleotide cGAMP | |
| CN111378707B (en) | In-vitro cell-free protein synthesis system and application thereof | |
| JP4972412B2 (en) | E. Method for large-scale production of plasmid DNA by coli fermentation | |
| CN105695551B (en) | A kind of biological method preparing dehydroepiandros-sterone | |
| Anand et al. | Comparative study for the production of mycophenolic acid using penicillium brevicompactum in batch, fed-batch and continuous fermentation process | |
| CN101974585A (en) | Process for producing antiviral medicament ribavirin by using microorganic enzymic method through enzyme production and fermentation of microorganisms | |
| CN106834391A (en) | A kind of formula and method based on artificial multienzyme biochemical reaction network synthetic protein | |
| CN102321643B (en) | Optimized DNA (Deoxyribonucleic Acid) molecule for coding ADI (Aiginine Deiminase) and engineering bacteria for expressing ADI | |
| CN116731941B (en) | An autonomous dynamic regulation method for improving the production performance of 2'-fucosyllactose | |
| Schweiger et al. | DNA-dependent in vitro synthesis of bacteriophage enzymes | |
| CN101285085A (en) | A kind of method utilizing the whole cell to catalyze the synthesis of adenosylmethionine | |
| CN103589769A (en) | High density fermentation method of recombinant porcine interferon alpha 1 (rPoIFN alpha 1) gene engineering bacteria | |
| CN111235084B (en) | Recombinant Escherichia coli engineering bacteria and method for preparing S-adenosylmethionine using the same | |
| CN115851694A (en) | Preparation method and application of immobilized enzyme for synthesizing 2' -fluoro-deoxyribonucleoside | |
| CN115975828A (en) | Yeast engineering bacterium for producing cordycepin and application | |
| CN115433750A (en) | A kind of preparation method of nicotinamide mononucleotide | |
| CN110157722B (en) | A recombinant strain and its construction method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170111 |
|
| WW01 | Invention patent application withdrawn after publication |